Balancing risks and therapeutic benefits. About adjuvant tamoxifen treatment for breast cancer patients

被引:7
|
作者
Sarradon-Eck, Aline [1 ]
Pellegrini, Isabelle [2 ]
机构
[1] MMSH, Ctr Norbert Elias, Equipe GReCSS PAS Anthropol Sante, F-130949 Aix En Provence, France
[2] Inst Paoli Calmette, INSERM, UMR SE4S 912, F-13273 Marseille 09, France
来源
SCIENCES SOCIALES ET SANTE | 2012年 / 30卷 / 01期
关键词
TREATMENT DECISION-MAKING; MEDICAL UNCERTAINTY; WOMENS PERCEPTIONS; CHEMOTHERAPY; HEALTH; EXPERIENCE;
D O I
10.3917/sss.301.0047
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
One of the main tools available for making bio-medical decisions about the best treatment to prescribe is the risk-benefit ratio. This article takes a contextual approach to the decision-making processes involved in the prescription of adjuvant tamoxifen as a mean of reducing the risk of relapse of breast cancer. Using anthropological descriptive methods, it examines the discrepancy between patients' and doctors' perceptions of the risks and benefits of the treatment and analyses their underlying logics. Representations of women are related to cancer (fear of the disease), its treatment (efficacy) and tamoxifen (fear of hormones and aging), and can lead to a symbolic hierarchy of treatments, whereas doctors' professional practices focus mainly on the prevention of the recurrence of cancers.
引用
收藏
页码:47 / 71
页数:25
相关论文
共 50 条
  • [21] Taxanes in the adjuvant treatment of node-negative breast cancer patients
    Ozdemir, N.
    Aksoy, S.
    Zengin, N.
    Altundag, K.
    JOURNAL OF BUON, 2012, 17 (01): : 27 - 32
  • [22] Implications of lymphatic mapping for staging and adjuvant treatment of patients with breast cancer
    Nieweg, OE
    Bartelink, H
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (02) : 179 - 181
  • [23] CNF combination as adjuvant treatment in breast cancer patients is well tolerated
    Hirvikoski, PP
    Kumpulainen, EJ
    Johansson, RT
    ANTI-CANCER DRUGS, 1997, 8 (04) : 376 - 378
  • [24] Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer
    Jordan, V. Craig
    ENDOCRINE-RELATED CANCER, 2014, 21 (03) : R235 - R246
  • [25] Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen
    Dominick, Sally
    Hickey, Martha
    Chin, Jason
    Su, H. Irene
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (12):
  • [26] Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen
    Chin, Jason
    Konje, Justin C.
    Hickey, Martha
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (04):
  • [27] Communicating Benefits and Risks of Screening for Prostate, Colon, and Breast Cancer
    Barrett, Bruce
    McKenna, Patrick
    FAMILY MEDICINE, 2011, 43 (04) : 248 - 253
  • [28] Therapeutic efficacy and toxicity of tamoxifen loaded PLA nanoparticles for breast cancer
    Pandey, Sanjeev K.
    Ghosh, Somenath
    Maiti, Pralay
    Haldar, Chandana
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2015, 72 : 309 - 319
  • [29] Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials
    Yan, Shunchao
    Li, Kai
    Jiao, Xin
    Zou, Huawei
    ONCOTARGETS AND THERAPY, 2015, 8 : 1433 - 1441
  • [30] Taxanes for adjuvant treatment of early breast cancer
    Willson, Melina L.
    Burke, Lucinda
    Ferguson, Thomas
    Ghersi, Davina
    Nowak, Anna K.
    Wicken, Nicholas
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (09):